NATO Fund Invests $35 Million in Biotech Startup to Counter Biological Threats

The NATO Innovation Fund has made its first major investment by co-leading a $35 million funding round for UK-based Portal Biotech. This groundbreaking move aims to bolster biosecurity defenses and improve NATO’s ability to address biological threats. Portal Biotech’s cutting-edge AI-powered technology uses biological sensors capable of detecting engineered pathogens at the single-molecule level, delivering results in mere hours.

The fund, established in 2022 after the Russian invasion of Ukraine, plans to invest over $1 billion in advanced technologies to strengthen NATO’s defenses. Portal Biotech’s portable instruments can detect and monitor pathogens in real-time, making them ideal for field operations, pandemic prevention, and water safety monitoring. CEO Andy Heron explained, “This technology doesn’t just detect known pathogens—it identifies unknown threats as well.”

Beyond biosecurity, Portal Biotech’s innovations are expected to support precision medicine and drug discovery. Investors in this funding round include Earlybird Venture Capital, Pillar VC, and British Business Bank, among others. NATO’s investment underscores the urgency of addressing modern biological warfare risks and enhancing global health security.